Vortioxetine - Revision history

MDElliottMD: Tier 2 taxonomy consolidation: remove Category:Serotonin Reuptake Inhibitors

2026-05-21T18:28:29Z

Tier 2 taxonomy consolidation: remove Category:Serotonin Reuptake Inhibitors

← Older revision		Revision as of 18:28, 21 May 2026
Line 25:		Line 25:
	[[Category:Multimodal Serotonergic Agents]]		[[Category:Multimodal Serotonergic Agents]]
	[[Category:Multimodal Antidepressants]]		[[Category:Multimodal Antidepressants]]
	~~[[Category:Serotonin Reuptake Inhibitors]]~~

MDElliottMD: Em-dash sweep: replace em-dash with comma per project rule; PendellsCorner verbatim quotes preserved.

2026-05-19T03:16:12Z

Em-dash sweep: replace em-dash with comma per project rule; PendellsCorner verbatim quotes preserved.

← Older revision		Revision as of 03:16, 19 May 2026
Line 14:		Line 14:
	\| pregnancy = Limited data; weigh benefits/risks		\| pregnancy = Limited data; weigh benefits/risks
	\| legal = Rx		\| legal = Rx
	\| intro = '''Vortioxetine''' (brand name Trintellix in the US, formerly Brintellix) is a multimodal antidepressant FDA-approved in 2013 for major depressive disorder. Beyond SERT inhibition, it directly modulates multiple serotonin receptor subtypes: 5HT1A agonism, 5HT1B partial agonism, and 5HT3, 5HT7, and 5HT1D antagonism. This combination produces, via disinhibition, downstream increases in not only serotonin but also norepinephrine, dopamine, acetylcholine, histamine, and glutamate — the hypothesized basis for its '''pro-cognitive effects''' (improved processing speed) that have distinguished it in trials of MDD with cognitive symptoms.		\| intro = '''Vortioxetine''' (brand name Trintellix in the US, formerly Brintellix) is a multimodal antidepressant FDA-approved in 2013 for major depressive disorder. Beyond SERT inhibition, it directly modulates multiple serotonin receptor subtypes: 5HT1A agonism, 5HT1B partial agonism, and 5HT3, 5HT7, and 5HT1D antagonism. This combination produces, via disinhibition, downstream increases in not only serotonin but also norepinephrine, dopamine, acetylcholine, histamine, and glutamate, the hypothesized basis for its '''pro-cognitive effects''' (improved processing speed) that have distinguished it in trials of MDD with cognitive symptoms.

	The ondansetron-like 5HT3 antagonism reduces the GI side effects common to pure SSRIs (less nausea than typical SERT inhibitors). Sexual side effects appear to be lower than with SSRIs but still occur.		The ondansetron-like 5HT3 antagonism reduces the GI side effects common to pure SSRIs (less nausea than typical SERT inhibitors). Sexual side effects appear to be lower than with SSRIs but still occur.

Maintenance script: Expand Vortioxetine with Stahl-sourced detail (with skepticism)

2026-05-16T02:03:45Z

Expand Vortioxetine with Stahl-sourced detail (with skepticism)

← Older revision		Revision as of 02:03, 16 May 2026
Line 1:		Line 1:
	{{MedTemplate		{{MedTemplate
	~~\| generic = Vortioxetine~~		\| brand = Trintellix (US), Brintellix (formerly)
	\| brand = Trintellix		\| classes = Multimodal antidepressant: SERT inhibitor + 5HT1A agonist + 5HT1B partial agonist + 5HT3/5HT7 antagonist
	~~\| structure =~~		\| mechanism = Sometimes called a 'serotonin modulator and stimulator.' Combines: SERT inhibition (raises 5-HT) + direct 5HT1A receptor agonism + 5HT1B partial agonism (heteroreceptor) + 5HT3, 5HT7, 5HT1D antagonism. Net effect: increased 5-HT, NE, DA, ACh, histamine, glutamate via disinhibition of multiple downstream circuits. Stahl emphasizes the 5HT3 antagonism + 5HT7 antagonism for the pro-cognitive effects.
	\| classes = ~~Antidepressant~~		\| uses = Major depressive disorder in adults (FDA-approved 2013). Notable for evidence of cognitive benefit (processing speed) that distinguishes it from other antidepressants.
	\| mechanism = ~~Multimodal serotonergic agent~~		\| starting_dose = 10 mg PO once daily; may increase to 20 mg as tolerated, or decrease to 5 mg if needed
	\| uses =		\| preparations = 5 mg, 10 mg, 20 mg tablets
	\| starting_dose =		\| fda_max = 20 mg/d
	\| preparations =		\| routes = Oral
	\| fda_max =		\| onset = Typical antidepressant 4-6 week onset
	\| routes =		\| duration = Daily dosing
	\| onset =		\| halflife = ~66 hours
	\| duration =		\| bioavailability = ~75%
	\| halflife =		\| pregnancy = Limited data; weigh benefits/risks
	\| bioavailability =		\| legal = Rx
	\| pregnancy =		\| intro = '''Vortioxetine''' (brand name Trintellix in the US, formerly Brintellix) is a multimodal antidepressant FDA-approved in 2013 for major depressive disorder. Beyond SERT inhibition, it directly modulates multiple serotonin receptor subtypes: 5HT1A agonism, 5HT1B partial agonism, and 5HT3, 5HT7, and 5HT1D antagonism. This combination produces, via disinhibition, downstream increases in not only serotonin but also norepinephrine, dopamine, acetylcholine, histamine, and glutamate — the hypothesized basis for its '''pro-cognitive effects''' (improved processing speed) that have distinguished it in trials of MDD with cognitive symptoms.
	\| legal =
	\| intro =		The ondansetron-like 5HT3 antagonism reduces the GI side effects common to pure SSRIs (less nausea than typical SERT inhibitors). Sexual side effects appear to be lower than with SSRIs but still occur.
	~~\| pharmacokinetics =~~		\| pharmacodynamics= SERT inhibition + 5HT1A agonism + 5HT1B partial agonism + 5HT3, 5HT7, 5HT1D antagonism. The 5HT3 antagonism (similar to ondansetron) may underlie reduced GI side effects. The 5HT7 antagonism may underlie pro-cognitive effects.
	\| pharmacodynamics =		\| effects = Nausea (most common; less than typical SSRIs), constipation, vomiting, sexual dysfunction (less than SSRIs but present). Lower rate of discontinuation symptoms due to long half-life.
	~~\| indications =~~		\| interactions = <pharmaInteractions/>
	~~\| dosing~~ =
	\| effects =
	\| interactions = <pharmaInteractions/>
	~~\| pregnancy_details =~~
	~~\| monitoring =~~
	~~\| counseling =~~
	~~\| anecdotes =~~
	~~\| seealso =~~
	~~\| references =~~
	}}		}}

	[[Category:Antidepressants]]		[[Category:Antidepressants]]
	[[Category:Multimodal Serotonergic Agents]]		[[Category:Multimodal Serotonergic Agents]]
			[[Category:Multimodal Antidepressants]]
			[[Category:Serotonin Reuptake Inhibitors]]

MDElliottMD: Comprehensive categorization: +Multimodal Serotonergic Agents

2026-05-15T18:42:07Z

Comprehensive categorization: +Multimodal Serotonergic Agents

← Older revision		Revision as of 18:42, 15 May 2026
Line 32:		Line 32:

	[[Category:Antidepressants]]		[[Category:Antidepressants]]
			[[Category:Multimodal Serotonergic Agents]]

MDElliottMD: Pharmacopedia: add

2026-05-14T03:31:13Z

Pharmacopedia: add <pharmaInteractions/>

← Older revision		Revision as of 03:31, 14 May 2026
Line 22:		Line 22:
	\| dosing =		\| dosing =
	\| effects =		\| effects =
	\| interactions =		\| interactions = <pharmaInteractions/>
	\| pregnancy_details =		\| pregnancy_details =
	\| monitoring =		\| monitoring =

MDElliottMD: Pharmacopedia: remove contraindications parameter

2026-05-14T02:40:53Z

Pharmacopedia: remove contraindications parameter

← Older revision		Revision as of 02:40, 14 May 2026
Line 22:		Line 22:
	\| dosing =		\| dosing =
	\| effects =		\| effects =
	~~\| contraindications =~~
	\| interactions =		\| interactions =
	\| pregnancy_details =		\| pregnancy_details =

MDElliottMD: Added empty fda_max parameter to MedTemplate call

2026-05-13T02:32:38Z

Added empty fda_max parameter to MedTemplate call

← Older revision		Revision as of 02:32, 13 May 2026
Line 8:		Line 8:
	\| starting_dose =		\| starting_dose =
	\| preparations =		\| preparations =
			\| fda_max =
	\| routes =		\| routes =
	\| onset =		\| onset =
Line 32:		Line 33:

	[[Category:Antidepressants]]		[[Category:Antidepressants]]

MDElliottMD: Expand stub to full MedTemplate parameter set

2026-05-13T01:00:00Z

Expand stub to full MedTemplate parameter set

@@ Line 1: / Line 1: @@
 {{MedTemplate
-| generic           = Vortioxetine
+| generic            = Vortioxetine
-| brand             = Trintellix
+| brand              = Trintellix
-| classes           = Antidepressant
+| structure          =
-| mechanism         = Multimodal serotonergic agent
+| classes            = Antidepressant
 }}
 [[Category:Antidepressants]]

MDElliottMD: Auto-created stub

2026-05-13T00:00:00Z

Auto-created stub

New page

{{MedTemplate
| generic = Vortioxetine
| brand = Trintellix
| classes = Antidepressant
| mechanism = Multimodal serotonergic agent
}}
[[Category:Antidepressants]]